Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions.

Fornaro L, Vasile E, Aprile G, Goetze TO, Vivaldi C, Falcone A, Al-Batran SE.

Cancer Treat Rev. 2018 Jun 18;69:90-100. doi: 10.1016/j.ctrv.2018.06.012. [Epub ahead of print] Review.

PMID:
29957366
2.

Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors.

Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, Clerico MA, Fornaro L.

Cancer Treat Rev. 2018 May 17;69:11-20. doi: 10.1016/j.ctrv.2018.05.010. [Epub ahead of print] Review.

PMID:
29860024
3.

Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.

Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, Barni S, Delfanti S, De Vita F, Di Costanzo F, Milella M, Cella CA, Berardi R, Cataldo I, Scarpa A, Basile D, Mazzuca F, Graziano G, Argentiero A, Santini D, Reni M, Cascinu S, Silvestris N.

Pancreas. 2018 Jul;47(6):759-771. doi: 10.1097/MPA.0000000000001063.

PMID:
29771769
4.

Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol.

Casadei Gardini A, Faloppi L, Aprile G, Brunetti O, Caparello C, Corbelli J, Chessa L, Bruno D, Ercolani G, Leonetti A, de Stefano G, Farella N, Foschi FG, Lanzi A, Dadduzio V, Marisi G, Masi G, Negri FV, Pagan F, Santini D, Scarpi E, Silletta M, Silvestris N, Tamburini E, Tassinari D, Vivaldi C, Gentilucci UV, Zagonel V, Calvetti L, Cascinu S, Frassineti GL, Scartozzi M.

Tumori. 2017 Dec 1:tj5000704. doi: 10.5301/tj.5000704. [Epub ahead of print]

PMID:
29739298
5.

Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.

Bonotto M, Basile D, Gerratana L, Pelizzari G, Bartoletti M, Vitale MG, Fanotto V, Lisanti C, Mansutti M, Minisini AM, Aprile G, De Laurentiis M, Montemurro F, Del Mastro L, Puglisi F.

Breast. 2018 Aug;40:45-52. doi: 10.1016/j.breast.2018.04.011. Epub 2018 Apr 19.

PMID:
29679936
6.

Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.

Pastorino A, Di Bartolomeo M, Maiello E, Iaffaioli V, Ciuffreda L, Fasola G, Di Costanzo F, Frassineti GL, Marchetti P, Antoniotti C, Leone F, Zaniboni A, Aprile G, Zilocchi C, Sobrero A, Bordonaro R.

Clin Colorectal Cancer. 2018 Mar 8. pii: S1533-0028(18)30050-1. doi: 10.1016/j.clcc.2018.03.002. [Epub ahead of print]

7.

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, de Braud F, Mazzaferro V, Falcone A, Pietrantonio F.

Br J Cancer. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13.

PMID:
29531324
8.

MGMT pyrosequencing-based cut-off methylation level and clinical outcome in patients with glioblastoma multiforme.

Gurrieri L, De Carlo E, Gerratana L, De Maglio G, Macerelli M, Pisa FE, Masiero E, Aprile G, Follador A, Puglisi F, Fasola G, Rizzato S, Pizzolitto S.

Future Oncol. 2018 Apr;14(8):699-707. doi: 10.2217/fon-2017-0437. Epub 2018 Mar 9.

PMID:
29521523
9.

CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric Cancer.

Fornaro L, Scartozzi M, Aprile G.

J Clin Oncol. 2018 Apr 10;36(11):1178-1179. doi: 10.1200/JCO.2017.76.6493. Epub 2018 Feb 28. No abstract available.

PMID:
29489431
10.

Outcome measures for children with movement disorders.

Pagliano E, Baranello G, Masson R, Foscan M, Arnoldi MT, Marchi A, Aprile G, Pantaleoni C.

Eur J Paediatr Neurol. 2018 May;22(3):346-353. doi: 10.1016/j.ejpn.2018.01.014. Epub 2018 Feb 8. Review.

PMID:
29475818
11.

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.

Cremolini C, Antoniotti C, Lonardi S, Aprile G, Bergamo F, Masi G, Grande R, Tonini G, Mescoli C, Cardellino GG, Coltelli L, Salvatore L, Corsi DC, Lupi C, Gemma D, Ronzoni M, Dell'Aquila E, Marmorino F, Di Fabio F, Mancini ML, Marcucci L, Fontanini G, Zagonel V, Boni L, Falcone A.

JAMA Oncol. 2018 Apr 1;4(4):529-536. doi: 10.1001/jamaoncol.2017.5314.

PMID:
29450468
12.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2018 Feb;23(2):272. doi: 10.1634/theoncologist.2017-0158erratum. No abstract available.

13.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.

PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

14.

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M.

Clin Cancer Res. 2018 Mar 1;24(5):1082-1089. doi: 10.1158/1078-0432.CCR-17-2781. Epub 2017 Dec 5.

PMID:
29208673
15.

Neoadjuvant chemotherapy in oesophageal adenocarcinoma.

Fornaro L, Aprile G.

Lancet Oncol. 2017 Nov;18(11):e640. doi: 10.1016/S1470-2045(17)30813-6. Epub 2017 Oct 31. No abstract available.

PMID:
29208394
16.

Orthodontic management by functional activator treatment: a case report.

Aprile G, Ortu E, Cattaneo R, Pietropaoli D, Giannoni M, Monaco A.

J Med Case Rep. 2017 Dec 2;11(1):336. doi: 10.1186/s13256-017-1505-y.

17.

Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.

Han van Krieken J, Kafatos G, Bennett J, Mineur L, Tomášek J, Rouleau E, Fabian P, De Maglio G, García-Alfonso P, Aprile G, Parkar P, Downey G, Demonty G, Trojan J.

BMC Cancer. 2017 Nov 28;17(1):798. doi: 10.1186/s12885-017-3740-4. Review.

18.

Magnetization switching in high-density magnetic nanodots by a fine-tune sputtering process on a large-area diblock copolymer mask.

Barrera G, Celegato F, Coïsson M, Manzin A, Ferrarese Lupi F, Seguini G, Boarino L, Aprile G, Perego M, Tiberto P.

Nanoscale. 2017 Nov 9;9(43):16981-16992. doi: 10.1039/c7nr04295g.

PMID:
29077107
19.

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.

Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M.

Oncotarget. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12. Review.

20.

Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.

Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M.

Eur J Cancer. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3.

PMID:
28985579
21.

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

Fornaro L, Fanotto V, Musettini G, Uccello M, Rimassa L, Vivaldi C, Fontanella C, Leone F, Giampieri R, Rosati G, Lencioni M, Santini D, Di Donato S, Tomasello G, Brunetti O, Pietrantonio F, Bergamo F, Scartozzi M, Avallone A, Lutrino SE, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Cordio S, Vasile E, Aprile G.

Future Oncol. 2017 Oct;13(25):2265-2275. doi: 10.2217/fon-2017-0246. Epub 2017 Oct 4. Erratum in: Future Oncol. 2018 Mar;14 (6):577.

PMID:
28976226
22.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

Fanotto V, Uccello M, Pecora I, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Ferrari L, Bordonaro R, Vivaldi C, Gerratana L, Bozzarelli S, Filippi R, Bilancia D, Russano M, Aprile G.

Oncologist. 2017 Dec;22(12):1463-1469. doi: 10.1634/theoncologist.2017-0158. Epub 2017 Aug 31. Erratum in: Oncologist. 2018 Feb;23 (2):272.

PMID:
28860412
23.

Intensive strength and balance training with the Kinect console (Xbox 360) in a patient with CMT1A.

Pagliano E, Foscan M, Marchi A, Corlatti A, Aprile G, Riva D.

Dev Neurorehabil. 2017 Aug 1:1-4. doi: 10.1080/17518423.2017.1354091. [Epub ahead of print]

PMID:
28762860
24.

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).

Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD.

ESMO Open. 2017 Apr 12;2(1):e000147. doi: 10.1136/esmoopen-2016-000147. eCollection 2017. Review.

25.

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury.

Cinausero M, Aprile G, Ermacora P, Basile D, Vitale MG, Fanotto V, Parisi G, Calvetti L, Sonis ST.

Front Pharmacol. 2017 Jun 8;8:354. doi: 10.3389/fphar.2017.00354. eCollection 2017. Review.

26.

Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?

Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M.

Crit Rev Oncol Hematol. 2017 Jul;115:1-12. doi: 10.1016/j.critrevonc.2017.03.025. Epub 2017 Apr 20. Review.

PMID:
28602164
27.

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest.

BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

28.

Molecular classifications of gastric cancers: Novel insights and possible future applications.

Garattini SK, Basile D, Cattaneo M, Fanotto V, Ongaro E, Bonotto M, Negri FV, Berenato R, Ermacora P, Cardellino GG, Giovannoni M, Pella N, Scartozzi M, Antonuzzo L, Silvestris N, Fasola G, Aprile G.

World J Gastrointest Oncol. 2017 May 15;9(5):194-208. doi: 10.4251/wjgo.v9.i5.194. Review.

29.

Sarcopenia in gastric cancer: when the loss costs too much.

Ongaro E, Buoro V, Cinausero M, Caccialanza R, Turri A, Fanotto V, Basile D, Vitale MG, Ermacora P, Cardellino GG, Nicoletti L, Fornaro L, Casadei-Gardini A, Aprile G.

Gastric Cancer. 2017 Jul;20(4):563-572. doi: 10.1007/s10120-017-0722-9. Epub 2017 May 5. Review.

PMID:
28477106
30.

Immunotherapeutic approaches for hepatocellular carcinoma.

Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O.

Oncotarget. 2017 May 16;8(20):33897-33910. doi: 10.18632/oncotarget.15406. Review.

31.

Toward Lateral Length Standards at the Nanoscale Based on Diblock Copolymers.

Aprile G, Ferrarese Lupi F, Fretto M, Enrico E, De Leo N, Boarino L, Volpe FG, Seguini G, Sparnacci K, Gianotti V, Laus M, Garnæs J, Perego M.

ACS Appl Mater Interfaces. 2017 May 10;9(18):15685-15697. doi: 10.1021/acsami.7b00509. Epub 2017 Apr 26.

PMID:
28397488
32.

Immunotherapy for colorectal cancer: where are we heading?

Basile D, Garattini SK, Bonotto M, Ongaro E, Casagrande M, Cattaneo M, Fanotto V, De Carlo E, Loupakis F, Urbano F, Negri FV, Pella N, Russano M, Brunetti O, Scartozzi M, Santini D, Silvestris N, Casadei Gardini A, Puzzoni M, Calvetti L, Cardarelli N, Aprile G.

Expert Opin Biol Ther. 2017 Jun;17(6):709-721. doi: 10.1080/14712598.2017.1315405. Epub 2017 Apr 13. Review. Erratum in: Expert Opin Biol Ther. 2017 Jun;17 (6):791.

PMID:
28375039
33.

Immunotherapy for gastric cancers: emerging role and future perspectives.

Bonotto M, Garattini SK, Basile D, Ongaro E, Fanotto V, Cattaneo M, Cortiula F, Iacono D, Cardellino GG, Pella N, Fasola G, Antonuzzo L, Silvestris N, Aprile G.

Expert Rev Clin Pharmacol. 2017 Jun;10(6):609-619. doi: 10.1080/17512433.2017.1313113. Epub 2017 Apr 10. Review.

PMID:
28349740
34.

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.

Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators.

Ann Oncol. 2017 Dec 1;28(12):3110. doi: 10.1093/annonc/mdx021. No abstract available.

PMID:
28327986
35.

Multimodal treatment of resectable pancreatic ductal adenocarcinoma.

Silvestris N, Brunetti O, Vasile E, Cellini F, Cataldo I, Pusceddu V, Cattaneo M, Partelli S, Scartozzi M, Aprile G, Casadei Gardini A, Morganti AG, Valentini V, Scarpa A, Falconi M, Calabrese A, Lorusso V, Reni M, Cascinu S.

Crit Rev Oncol Hematol. 2017 Mar;111:152-165. doi: 10.1016/j.critrevonc.2017.01.015. Epub 2017 Feb 4. Review.

PMID:
28259290
36.

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Pietrantonio F, Battaglin F, Avallone A, Scartozzi M, Lutrino ES, Melisi D, Antonuzzo L, Pellegrino A, Torri V, Aprile G.

Gastric Cancer. 2017 Sep;20(5):825-833. doi: 10.1007/s10120-016-0681-6. Epub 2016 Dec 27.

PMID:
28028664
37.

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A.

Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

PMID:
27986363
38.

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.

Pietrantonio F, Miceli R, Rimassa L, Lonardi S, Aprile G, Mennitto A, Marmorino F, Bozzarelli S, Antonuzzo L, Tamburini E, Morano F, Rossini D, Battaglin F, Baretti M, Berenato R, Formica V, Mosconi S, Petrelli F, Ghidini M, Loupakis F, Spada D, Cinieri S, Beretta G, Falcone A, de Braud F, Cremolini C.

Ann Oncol. 2017 Mar 1;28(3):555-561. doi: 10.1093/annonc/mdw627.

PMID:
27864220
39.

Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement.

Gori S, Pinto C, Caminiti C, Aprile G, Marchetti P, Perrone F, Di Maio M, Omodeo Salè E, Mancuso A, De Cicco M, Di Costanzo F, Crispino S, Passalacqua R, Merlano M, Zagonel V, Fioretto L, Micallo G, Labianca R, Bordonaro R, Comandone A, Spinsanti S, Iacono C, Nicolis F; AIOM (Italian Medical Oncology Association) and AIOM Foundation.

Tumori. 2016 Dec 1;102(6):e25-e27. doi: 10.5301/tj.5000582.

PMID:
27791235
40.

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.

Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators.

Ann Oncol. 2016 Nov;27(11):2074-2081. Epub 2016 Aug 29. Erratum in: Ann Oncol. 2017 Dec 1;28(12 ):3110.

PMID:
27573560
41.

Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Pinto C, Antonuzzo L, Porcu L, Aprile G, Maiello E, Masi G, Petrelli F, Scartozzi M, Torri V, Barni S.

Clin Colorectal Cancer. 2017 Jun;16(2):e61-e72. doi: 10.1016/j.clcc.2016.08.006. Epub 2016 Aug 31. Review.

42.

Wernicke encephalopathy and systemic sclerosis: rare association of rare conditions.

Sciacca G, Fermo SL, Aprile G, Nicoletti A, Zappia M.

Neurol Sci. 2017 Jan;38(1):203-205. doi: 10.1007/s10072-016-2704-9. Epub 2016 Sep 2. No abstract available.

PMID:
27590483
43.

Comparison of the molecular profile of brain metastases from colorectal cancer and corresponding primary tumors.

Aprile G, Casagrande M, De Maglio G, Fontanella C, Rihawi K, Bonotto M, Pisa FE, Tuniz F, Pizzolitto S, Fasola G.

Future Oncol. 2017 Jan;13(2):135-144. Epub 2016 Aug 31.

PMID:
27578453
44.

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M.

Int J Cancer. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408. Epub 2016 Sep 16.

45.

HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.

Fanotto V, Ongaro E, Rihawi K, Avallone A, Silvestris N, Fornaro L, Vasile E, Antonuzzo L, Leone F, Rosati G, Giuliani F, Bordonaro R, Scartozzi M, De Maglio G, Negri FV, Fasola G, Aprile G.

Oncotarget. 2016 Oct 18;7(42):69060-69074. doi: 10.18632/oncotarget.11264. Review.

46.

Effect of carrier tunneling on the structure of Si nanowires fabricated by metal assisted etching.

Rezvani SJ, Gunnella R, Neilson D, Boarino L, Croin L, Aprile G, Fretto M, Rizzi P, Antonioli D, Pinto N.

Nanotechnology. 2016 Aug 26;27(34):345301. doi: 10.1088/0957-4484/27/34/345301. Epub 2016 Jul 15.

PMID:
27420163
47.

An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.

Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F, Zanotto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, Melisi D.

Clin Cancer Res. 2016 Dec 15;22(24):6164-6175. Epub 2016 Jun 7.

48.

The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M.

Target Oncol. 2016 Oct;11(5):593-603. Review.

PMID:
27184491
49.

Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.

Aprile G, Ferrari L, Cremolini C, Bergamo F, Fontanella C, Battaglin F, Rihawi K, Lonardi S, Loupakis F, Scartozzi M.

Expert Rev Clin Pharmacol. 2016 Jul;9(7):877-85. doi: 10.1080/17512433.2016.1182861. Epub 2016 Jun 2. Review.

PMID:
27149032
50.

Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.

Giampieri R, Salvatore L, Del Prete M, Prochilo T, D'Anzeo M, Loretelli C, Loupakis F, Aprile G, Maccaroni E, Andrikou K, Bianconi M, Bittoni A, Faloppi L, Demurtas L, Montironi R, Scarpelli M, Falcone A, Zaniboni A, Scartozzi M, Cascinu S.

Sci Rep. 2016 Apr 27;6:25195. doi: 10.1038/srep25195.

Supplemental Content

Loading ...
Support Center